Streetbeat News

Revenues

CRDO

Credo Technology Group (NASDAQ:CRDO) has received mixed analyst ratings over the past three months, with a recent trend towards more bullish perspectives. The average 12-month price target for CRDO has been raised to $26.2, indicating a 10.32% increase from the previous target. Analysts from Mizuho, Needham, and Goldman Sachs have adjusted their ratings and price targets, reflecting optimism about CRDO's future performance despite challenges in revenue growth and profitability.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:00 pm

VRDN

Viridian Therapeutics (NASDAQ:VRDN) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for VRDN has been adjusted to $35.83, down from $37.00, reflecting a 3.16% decrease. The company, a clinical-stage biopharmaceutical firm focusing on thyroid eye disease treatments, faces financial challenges, including a significant revenue decline and below-industry benchmarks in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:00 pm

CETX

Cemtrex Inc. (NASDAQ:CETX) issued a shareholder letter providing a corporate update, highlighting restructuring efforts, investments, and financial performance. The letter, from CEO Saagar Govil, discusses the company's exit from certain businesses, the promising outlook of its Security and Industrial segments, and significant improvements in financial metrics. The company owns Vicon Industries and Advanced Industrial Services, which have shown strong sales growth and operational improvements. The letter emphasizes Cemtrex's focus on generating higher returns than the S&P 500 and the potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:38 pm

NNDM

Nano Dimension announced the sale of a second 3D printer for electronics to an existing customer, indicating repeat business and potential growth in customer satisfaction and product reliability.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:36 pm

NVO

A Pew Research Center survey reveals skepticism among Americans regarding the effectiveness of weight loss drugs Ozempic and Wegovy, produced by Novo Nordisk (NYSE:NVO), in significantly reducing the country's obesity rate. Despite the drugs' FDA approval for managing Type 2 diabetes and long-term weight management, only 35% of respondents believe they will somewhat reduce obesity. Concerns include rising drug prices, counterfeit versions, and the need for food companies to adjust their offerings.

Portfolio Pulse from Benzinga Neuro

February 28, 2024 | 1:31 pm

ALTM

LZM

NEM

The article highlights the top 3 materials stocks that are currently oversold according to their RSI values, suggesting potential buying opportunities. Arcadium Lithium plc (ALTM) reported better-than-expected quarterly earnings, Newmont Corporation (NEM) announced a 24% Y/Y increase in fourth-quarter revenue, and Lifezone Metals Limited (LZM) revealed a development plan for the Kabanga Nickel Project. Despite positive developments, all three stocks have seen recent declines in their stock prices.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 1:31 pm

ICAD

iCAD, Inc. (NASDAQ:ICAD) showcased clinical data at ECR 2024, demonstrating the effectiveness of its AI-powered ProFound Detection in reducing breast interval cancer rates and recall rates, while also decreasing radiology reading workload. The company also introduced new features for ProFound Detection, aimed at improving mammogram readability for radiologists. Additionally, iCAD presented research on using Breast Arterial Calcification detection as a biomarker for cardiovascular disease in women. The company highlighted its expanded cloud platform and subscription licensing plans.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:27 pm

FWONA

Liberty Formula One Group (NASDAQ:FWONA) reported Q4 sales of $1.23 billion, missing the consensus estimate of $1.26 billion by 2.38%. However, this represents a 63.13% increase over the previous year's sales of $754.00 million.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:22 pm

BATRA

Liberty Braves Group (NASDAQ:BATRA) reported a Q4 2023 GAAP EPS of $(0.52) with baseball revenue at $52.9M and total revenue at $71.26M, surpassing analyst expectations by 25.02% and marking a 34.45% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:21 pm

GSAT

Globalstar projects its FY24 total revenue to be between $225M-$250M, which is below the estimated $251.5M. The company also forecasts an adjusted EBITDA margin of approximately 50%.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:16 pm